|
所属 |
大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 臨床腫瘍学講座 |
職務経歴（学内） 【 表示 ／ 非表示 】
-
2023年04月-継続中
秋田大学 大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 講師
-
2019年04月-2023年03月
秋田大学 大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 助教
-
2017年06月-2019年03月
秋田大学 医学部 寄附講座 寄附講座助教
学位論文 【 表示 ／ 非表示 】
-
A diarylpentanoid curcumin analog exhibits improved radioprotective potential in the intestinal mucosa
Koji Fukuda, Yoshihiko Uehara, Eiko Nakata
International Journal of Radiation Biology 92 ( 7 ) 388 - 394 2017年03月
国内共著
研究等業績 【 表示 ／ 非表示 】
-
Fukushi Y.
Journal of Pharmaceutical Health Care and Sciences ( Journal of Pharmaceutical Health Care and Sciences ) 12 ( 1 ) 2026年12月
研究論文（学術雑誌）
-
Fujita K.
Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 54 ( 11 ) 1165 - 1170 2024年11月
研究論文（学術雑誌）
BACKGROUND: The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin. METHODS: The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death. RESULTS: The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 (P < .001), concurrent chemotherapy (P = .002), albumin level (P = .005), C-reactive protein level (P = .013), and a mGPS of 2 (P = .014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin. CONCLUSION: Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.
-
PD-L1 expression in keratinocyte and infiltration of CD4 + T lymphocyte can predict a severe type of erythema multiforme major induced by the anti-PD-1 antibody, pembrolizumab.
Ryohei Kadoi, Taichi Yoshida, Mai Noto, Aya Toyoshima, Sino Fujii, Koji Fukuda, Kazuhiro Shimazu, Daiki Taguchi, Hanae Shinozaki, Naoki Kodama, Michihiro Kono, Hiroshi Nanjyo, Hiroyuki Shibata
International cancer conference journal 13 ( 3 ) 268 - 274 2024年07月
研究論文（学術雑誌）
UNLABELLED: Skin toxicity is the most common adverse event of treatment with immune check point inhibitors. Among them, erythema multiforme is a rare occurrence with a frequency of 4%, with most of the cases developing grade 1/2 disease. We experienced high grade erythema multiforme major developing with pembrolizumab treatment for anal canal cancer with extensive skin metastases. Steroid ointment was ineffective, and the skin lesions with blisters expanded to > 45% of the body surface area. The patient was at risk for symptom aggravation, and a pulse therapy with methylprednisolone and increasing the dose of oral prednisolone (1 mg/kg) were started. The skin lesions improved in 1.8 months. Unless urgent and appropriate treatments such as high dose steroid administration were conducted, the skin toxicities could not be controlled. The presence of CD4+ T cells and PD-L1+ keratinocytes in the skin biopsy might be a predictive marker of erythema multiforme major resistant to standard steroid treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13691-024-00676-4.
-
Fujita K.
Investigational New Drugs ( Investigational New Drugs ) 42 ( 3 ) 252 - 260 2024年06月
研究論文（学術雑誌）
The aim of the present study was to determine whether the trough plasma concentrations (C0) of regorafenib and its metabolites, the N-oxide metabolite (M-2) and the desmethyl N-oxide metabolite (M-5), in 21 patients receiving regorafenib therapy were affected by albumin-bilirubin (ALBI) grade. Regorafenib was administered at dosages ranging from 40 to 160 mg once daily on a 3-week-on, 1-week-off cycle. C0 values of regorafenib and its major metabolites were measured by high-performance liquid chromatography on day 8 after treatment initiation. The C0 values of regorafenib and metabolites M-2 and M-5 were significantly lower in patients with ALBI grade 2 as compared with grade 1 (P = 0.023, 0.003 and 0.017, respectively). The total C0 of regorafenib and its metabolites was significantly higher in ALBI grade 1 patients relative to grade 2 (3.489 μg/mL vs. 1.48 μg/mL; P = 0.009). The median relative dose intensity (RDI) of patients categorized as ALBI grade 2 was significantly lower than that of grade 1 patients (21.9% vs. 62.9%; P = 0.006). In 15 colorectal cancer patients among the total 21 patients, patients with ALBI grade 2 (n = 9) had a significantly shorter median overall survival time than patients with grade 1 (n = 6; P = 0.013). Administering a low dose of regorafenib to patients with ALBI grade 2 reduces the RDI of regorafenib and lowers treatment efficacy, as an appropriate C0 of regorafenib is not maintained. Monitoring the C0 of regorafenib regularly is necessary to guide dose adjustment.
-
Recent trends in bone metastasis treatments: A historical comparison using the new Katagiri score system.
Kenji Matsuda, Kazuhiro Shimazu, Hanae Shinozaki, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Kyoko Nomura, Hiroyuki Shibata
World journal of clinical cases 12 ( 15 ) 2499 - 2505 2024年05月
研究論文（学術雑誌）
BACKGROUND: Bone metastasis has various negative impacts. Activities of daily living (ADL) and quality of life (QOL) can be significantly decreased, survival may be impacted, and medical expenses may increase. It is estimated that at least 5% cancer patients might be suffering from bone metastases. In 2016, we published the Comprehensive Guidelines for the Diagnosis and Treatment of Bone Metastasis. Since then, the therapeutic outcomes for patients have gradually improved. As life expectancy is a major determinant of surgical intervention, the strategy should be modified if the prolongation of survival is to be achieved. AIM: To monitor how bone metastasis treatment has changed before and after launch of our guidelines for bone metastasis. METHODS: For advanced cancer patients with bone metastasis who visited the Department of Clinical Oncology at Akita University hospital between 2012 and 2023, parameters including the site and number of bone metastases, laboratory data, and survival time, were extracted from electronic medical records and the Katagiri score was calculated. The association with survival was determined for each factor. RESULTS: Data from 136 patients were obtained. The 1-year survival rate for the poor prognosis group with a higher Katagiri score was 20.0% in this study, which was 6% and an apparent improvement from 2014 when the scoring system was developed. Other factors significantly affecting survival included five or more bone metastases than less (P = 0.0080), and treatment with chemotherapy (P < 0.001), bone modifying agents (P = 0.0175) and immune checkpoint inhibitors (P = 0.0128). In recent years, advances in various treatment methods have extended the survival period for patients with advanced cancer. It is necessary not only to simply extend survival time, but also to maintain ADL and improve QOL. CONCLUSION: Various therapeutic interventions including surgical approach for bone metastasis, which is a disorder of locomotor organs, are increasingly required. Guidelines and scoring system for prognosis need to be revised promptly.
-
Shimoyachi R.
Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 56 ( 4 ) 489 - 495 2026年04月
-
Kosaka H.
Journal of Gastroenterology ( Journal of Gastroenterology ) 2026年
-
Kosaka H.
Annals of Gastroenterological Surgery ( Annals of Gastroenterological Surgery ) 2026年
-
Wada Y.
Gastric Cancer ( Gastric Cancer ) 28 ( 4 ) 712 - 717 2025年07月
-
Yoshida Taichi, Kodama Naoaki, Matsumoto Tomohiro, Taguchi Daiki, Shimazu Kazuhiro, Fukuda Koji, Shibata Hiroyuki
Internal Medicine ( 一般社団法人 日本内科学会 ) advpub ( 0 ) 1205 - 1209 2025年
<p>The optimal dose of chemotherapy for patients undergoing hemodialysis remains unclear. A 65-year-old man with diabetic nephropathy was treated with nivolumab plus modified FOLFOX6 therapy for recurrent gastric cancer with liver metastases. Oxaliplatin was reduced to 65 mg/m<sup>2</sup>, continuous infusion of 5-fluorouracil was initiated at 2,000 mg/m<sup>2</sup>, and bolus administration was discontinued. No nivolumab was administrated. Dose modification and discontinuation were performed depending on the patient's general condition and blood test during the treatment course. He received standard chemotherapy for gastric cancer; however, it was ineffective because of ascites and elevated CA125 levels. </p>